Circulating Interleukin-6 (IL-6) Levels Are Associated with Aortic Dimensions in Genetic Aortic Conditions

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Mar 19

PMID 30883599

Citations 8

Authors

Daishi Fujita

Liliana Preiss

Kenichi Aizawa

Federico Asch

Kim Eagle

Toru Suzuki

Affiliations

Soon will be listed here.

Abstract

Background: Biomarkers that reflect progression of dilatation of the aorta in patients with aortic conditions are needed as surrogate tools to assist in monitoring the condition in a non-invasive manner in combination with imaging procedures. This study aimed to investigate whether biomarkers are associated with aortic dimensions in patients enrolled in the Genetically-Triggered Thoracic Aortic Conditions (GenTAC) registry.

Methods: Plasma samples of 159 patients enrolled in the GenTAC registry were assessed for circulating biomarkers [interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), tissue inhibitor of metalloproteinase-2 (TIMP-2) and transforming growth factor-β1 (TGFβ1)]. Association of circulating biomarker levels with aortic dimensions was investigated.

Results: IL-6 showed significant positive correlations with aortic dimensions at each segment of the aorta, with the correlation increasing in more distal aortic regions (ascending aorta, R = 0.26, p = 0.004; proximal arch, R = 0.35, p<0.0001; transverse arch, R = 0.30, p = 0.0005; mid-descending thoracic aorta, R = 0.40, p<0.0001; thoracoabdominal aorta, R = 0.38, p<0.0001; suprarenal abdominal aorta, R = 0.42, p<0.0001; and infrarenal aorta, R = 0.43, p<0.0001). TIMP-1 showed a significant correlation albeit weaker than IL-6, and also showed increasing correlation towards the distal areas of the aorta.

Conclusions: Circulating IL-6 and TIMP-1 were associated with aortic dimensions in patients with aortopathies enrolled in the GenTAC cohort.

Citing Articles

Cardiovascular Outcomes in Aortopathy: GenTAC Registry of Genetically Triggered Aortic Aneurysms and Related Conditions.

Holmes K, Markwardt S, Eagle K, Devereux R, Weinsaft J, Asch F J Am Coll Cardiol. 2022; 79(21):2069-2081.

PMID: 35618343 PMC: 9205611. DOI: 10.1016/j.jacc.2022.03.367.

Is Thoracic Aortic Diameter an Independent Predictor of Cardiovascular Disease and Mortality? A Narrative Review.

Tadic M, Gherbesi E, Sala C, Carugo S, Cuspidi C Front Cardiovasc Med. 2022; 9:867026.

PMID: 35571154 PMC: 9098814. DOI: 10.3389/fcvm.2022.867026.

Ascending aortic dissecting aneurysm with rupture into the right atrium associated with COVID-19.

Kamanakeri D, Anoop A, Harikrishnan S, Gopalakrishnan A J Postgrad Med. 2022; 68(2):117-119.

PMID: 35417997 PMC: 9196298. DOI: 10.4103/jpgm.jpgm_903_21.

Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development.

Hossein Heydari A, Heydari S, Esmaeil Heidari M Cardiovasc Drugs Ther. 2021; 37(2):239-244.

PMID: 34826037 DOI: 10.1007/s10557-021-07294-9.

Polymorphisms of Pro-Inflammatory IL-6 and IL-1β Cytokines in Ascending Aortic Aneurysms as Genetic Modifiers and Predictive and Prognostic Biomarkers.

Scola L, Giarratana R, Marinello V, Cancila V, Pisano C, Ruvolo G Biomolecules. 2021; 11(7).

PMID: 34202072 PMC: 8301826. DOI: 10.3390/biom11070943.

References

Agg B, Benke K, Szilveszter B, Polos M, Daroczi L, Odler B . Possible extracardiac predictors of aortic dissection in Marfan syndrome. BMC Cardiovasc Disord. 2014; 14:47. PMC: 4021409. DOI: 10.1186/1471-2261-14-47. View

Akerman A, Stroud R, Barrs R, Grespin R, McDonald L, Larue R . Elevated Wall Tension Initiates Interleukin-6 Expression and Abdominal Aortic Dilation. Ann Vasc Surg. 2017; 46:193-204. PMC: 5894101. DOI: 10.1016/j.avsg.2017.10.001. View

Son B, Sawaki D, Tomida S, Fujita D, Aizawa K, Aoki H . Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma. Nat Commun. 2015; 6:6994. DOI: 10.1038/ncomms7994. View

Schmoker J, McPartland K, Fellinger E, Boyum J, Trombley L, Ittleman F . Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007; 133(1):155-61. DOI: 10.1016/j.jtcvs.2006.07.036. View

Habashi J, Doyle J, Holm T, Aziz H, Schoenhoff F, Bedja D . Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 2011; 332(6027):361-5. PMC: 3097422. DOI: 10.1126/science.1192152. View

Seppelt P, Schwill S, Weymann A, Arif R, Weber A, Zaradzki M . Loss of Endothelial Barrier in Marfan Mice (mgR/mgR) Results in Severe Inflammation after Adenoviral Gene Therapy. PLoS One. 2016; 11(2):e0148012. PMC: 4740453. DOI: 10.1371/journal.pone.0148012. View

Pope N, Salmon M, Johnston W, Lu G, Lau C, Upchurch Jr G . Interleukin-6 Receptor Inhibition Prevents Descending Thoracic Aortic Aneurysm Formation. Ann Thorac Surg. 2015; 100(5):1620-6. PMC: 11420933. DOI: 10.1016/j.athoracsur.2015.05.009. View

Ye P, Chen W, Wu J, Huang X, Li J, Wang S . GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency. J Clin Invest. 2013; 123(5):2317-31. PMC: 3635740. DOI: 10.1172/JCI67356. View

Kasashima S, Kawashima A, Zen Y, Ozaki S, Kasashima F, Endo M . Upregulated interleukins (IL-6, IL-10, and IL-13) in immunoglobulin G4-related aortic aneurysm patients. J Vasc Surg. 2017; 67(4):1248-1262. DOI: 10.1016/j.jvs.2016.12.140. View

10.

Ju X, Ijaz T, Sun H, LeJeune W, Vargas G, Shilagard T . IL-6 regulates extracellular matrix remodeling associated with aortic dilation in a fibrillin-1 hypomorphic mgR/mgR mouse model of severe Marfan syndrome. J Am Heart Assoc. 2014; 3(1):e000476. PMC: 3959679. DOI: 10.1161/JAHA.113.000476. View

11.

Radonic T, de Witte P, Groenink M, de Waard V, Lutter R, van Eijk M . Inflammation aggravates disease severity in Marfan syndrome patients. PLoS One. 2012; 7(3):e32963. PMC: 3316543. DOI: 10.1371/journal.pone.0032963. View

12.

Eagle K . Rationale and design of the National Registry of Genetically Triggered Thoracic Aortic Aneurysms and Cardiovascular Conditions (GenTAC). Am Heart J. 2009; 157(2):319-26. PMC: 2840718. DOI: 10.1016/j.ahj.2008.10.005. View

13.

Golledge J, Tsao P, Dalman R, Norman P . Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008; 118(23):2382-92. PMC: 2752737. DOI: 10.1161/CIRCULATIONAHA.108.802074. View

14.

Chung A, Yang H, Radomski M, van Breemen C . Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ Res. 2008; 102(8):e73-85. DOI: 10.1161/CIRCRESAHA.108.174367. View

15.

Neptune E, Frischmeyer P, Arking D, Myers L, Bunton T, Gayraud B . Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003; 33(3):407-11. DOI: 10.1038/ng1116. View

16.

Asch F, Yuriditsky E, Prakash S, Roman M, Weinsaft J, Weissman G . The Need for Standardized Methods for Measuring the Aorta: Multimodality Core Lab Experience From the GenTAC Registry. JACC Cardiovasc Imaging. 2016; 9(3):219-26. PMC: 4788536. DOI: 10.1016/j.jcmg.2015.06.023. View

17.

Mendoza D, Kochar M, Devereux R, Basson C, Min J, Holmes K . Impact of image analysis methodology on diagnostic and surgical classification of patients with thoracic aortic aneurysms. Ann Thorac Surg. 2011; 92(3):904-12. DOI: 10.1016/j.athoracsur.2011.03.130. View

18.

Chung A, Au Yeung K, Sandor G, Judge D, Dietz H, van Breemen C . Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome. Circ Res. 2007; 101(5):512-22. DOI: 10.1161/CIRCRESAHA.107.157776. View

19.

Folsom A, Yao L, Alonso A, Lutsey P, Missov E, Lederle F . Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015; 132(7):578-85. PMC: 4543558. DOI: 10.1161/CIRCULATIONAHA.115.016537. View

20.

Matt P, Schoenhoff F, Habashi J, Holm T, van Erp C, Loch D . Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 2009; 120(6):526-32. PMC: 2779568. DOI: 10.1161/CIRCULATIONAHA.108.841981. View